Difference between revisions of "LDN"
(→Physiological Impact) |
|||
Line 3: | Line 3: | ||
=Physiological Impact= | =Physiological Impact= | ||
− | * It specifically binds to Toll-like receptor 4, where it acts as an antagonist<ref name='2018-review'>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313374/</ref> | + | * Glial modulator- It specifically binds to Toll-like receptor 4, where it acts as an antagonist<ref name='2018-review'>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313374/</ref> |
* Transient opioid receptor blockade upregulates opioid signaling <ref name='2018-review'></ref> | * Transient opioid receptor blockade upregulates opioid signaling <ref name='2018-review'></ref> | ||
* The higher reactivity of immune cells and decreased growth of cancerous cells are both mediated by transient increase in opioid growth factor signaling<ref name='2018-review'></ref> | * The higher reactivity of immune cells and decreased growth of cancerous cells are both mediated by transient increase in opioid growth factor signaling<ref name='2018-review'></ref> | ||
+ | |||
=What Does It Treat= | =What Does It Treat= | ||
==Fibromyalgia== | ==Fibromyalgia== |
Latest revision as of 12:31, 22 December 2019
Contents
How To Take It
The typical dosage range is 0.25mg - 5mg / day. Usually one would start at the low end and slowly work up.
Physiological Impact
- Glial modulator- It specifically binds to Toll-like receptor 4, where it acts as an antagonist[1]
- Transient opioid receptor blockade upregulates opioid signaling [1]
- The higher reactivity of immune cells and decreased growth of cancerous cells are both mediated by transient increase in opioid growth factor signaling[1]
What Does It Treat
Fibromyalgia
http://fibrotrust.org/2012/09/15/ldm-low-dose-naltrexone/
Resources
http://www.ldninfo.org/index.htm#What_is_low_dose_naltrexone
Sources
https://www.buyldn.com/naltrexlow
Notes
LDN has less effect for some genotypes. (Like me - I was on it for a year and followed the increase protocol to a T, and noticed no difference. I am "rs1799971 6 154360797 AA"):
"Among 200+ alcoholics treated with naltrexone, rs1799971(G) carriers receiving the drug (even without behavioral intervention) had an increased percentage of days abstinent (p = .07) and a decreased percentage of heavy drinking days (p = .04) if treated with naltrexone vs. placebo, whereas rs1799971(A;A) homozygotes showed no medication differences. Upon treatment with naltrexone, 87% of rs1799971(G) carriers had a good clinical outcome, compared with only 55% of individuals with the (A;A) genotype (odds ratio, 5.75, CI: 1.88-17.54)[PMID 18250251OA-icon.png]" from http://www.snpedia.com/index.php/Rs1799971